Invention Application
- Patent Title: FACTOR XIa INHIBITORS
- Patent Title (中): 因子XIa抑制剂
-
Application No.: PCT/CN2015/084937Application Date: 2015-07-23
-
Publication No.: WO2016015593A1Publication Date: 2016-02-04
- Inventor: LIU, Weiguo , EDMONDSON, Scott D. , GUO, Zhuyan , SO, Sung-Sau , OGAWA, Anthony K. , KUANG, Rongze , WU, Heping , ALI, Amjad , GAO, Ying-Duo , JIANG, Yu , LI, Chunsing , YU, Tingting , PANDYA, Bhuamik , LIPPA, Blaise , ZHANG, Xin , BABER, Jon Christian , ROMERO, Jan Antoinette C. , ZHANG, Jing
- Applicant: MERCK SHARP & DOHME CORP. , LIU, Weiguo , EDMONDSON, Scott D. , GUO, Zhuyan , SO, Sung-Sau , OGAWA, Anthony K. , KUANG, Rongze , WU, Heping , ALI, Amjad , GAO, Ying-Duo , JIANG, Yu , LI, Chunsing , YU, Tingting , PANDYA, Bhuamik , LIPPA, Blaise , ZHANG, Xin , BABER, Jon Christian , ROMERO, Jan Antoinette C. , ZHANG, Jing
- Applicant Address: 126 East Lincoln Avenue Rahway New Jersey 07065 US
- Assignee: MERCK SHARP & DOHME CORP.,LIU, Weiguo,EDMONDSON, Scott D.,GUO, Zhuyan,SO, Sung-Sau,OGAWA, Anthony K.,KUANG, Rongze,WU, Heping,ALI, Amjad,GAO, Ying-Duo,JIANG, Yu,LI, Chunsing,YU, Tingting,PANDYA, Bhuamik,LIPPA, Blaise,ZHANG, Xin,BABER, Jon Christian,ROMERO, Jan Antoinette C.,ZHANG, Jing
- Current Assignee: MERCK SHARP & DOHME CORP.,LIU, Weiguo,EDMONDSON, Scott D.,GUO, Zhuyan,SO, Sung-Sau,OGAWA, Anthony K.,KUANG, Rongze,WU, Heping,ALI, Amjad,GAO, Ying-Duo,JIANG, Yu,LI, Chunsing,YU, Tingting,PANDYA, Bhuamik,LIPPA, Blaise,ZHANG, Xin,BABER, Jon Christian,ROMERO, Jan Antoinette C.,ZHANG, Jing
- Current Assignee Address: 126 East Lincoln Avenue Rahway New Jersey 07065 US
- Agency: WU, FENG & ZHANG CO.
- Priority: US62/029,758 20140728
- Main IPC: C07D233/54
- IPC: C07D233/54 ; C07D257/06 ; C07D263/30 ; C07D249/06 ; C07D285/04 ; C07D271/10 ; A61K31/4164 ; A61K31/4192 ; A61K31/422 ; A61K31/433 ; A61P7/02
Abstract:
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
Information query
